Liraglutide
Side effects
Options: Show MedDRA Preferred Terms
| Side effect | Data for drug | Placebo | Labels | |
|---|---|---|---|---|
| 1 | 2 | |||
| Headache | postmarketing, 9.1% - 9.3% | x | x | |
| Constipation | postmarketing, 4.8% - 9.9% | x | x | |
| Vomiting | postmarketing, 1.5% - 10.9% | x | x | |
| Abdominal distension | postmarketing | x | ||
| Pancreatitis acute | postmarketing | x | x | |
| Anaphylactic shock | postmarketing | x | x | |
| Angioedema | postmarketing | x | x | |
| Anorexia | postmarketing | x | ||
| Bronchitis | postmarketing | x | ||
| Infection | postmarketing | x | x | |
| Dehydration | postmarketing | x | x | |
| Diarrhoea | postmarketing, 8.9% - 17.1% | x | x | |
| Dizziness | postmarketing | x | ||
| Dyspepsia | postmarketing | x | x | |
| Dyspnoea | postmarketing | x | ||
| Oedema | postmarketing | x | ||
| Rash | postmarketing | x | x | |
| Fatigue | postmarketing | x | ||
| Flatulence | postmarketing | x | ||
| Gastritis | postmarketing | x | ||
| Gastrooesophageal reflux disease | postmarketing | x | ||
| Gastrointestinal disorder | postmarketing | x | ||
| Cardiac disorder | postmarketing | x | ||
| Hypersensitivity | postmarketing | x | x | |
| Hypoglycaemia | postmarketing | x | x | |
| Hypotension | postmarketing | x | ||
| Immune system disorder | postmarketing | x | ||
| Intestinal obstruction | postmarketing | x | ||
| Renal failure acute | postmarketing | x | x | |
| Renal failure chronic | postmarketing | x | ||
| Nasopharyngitis | postmarketing | x | ||
| Nausea | postmarketing, 8.5% - 28.4% | x | x | |
| Nervous system disorder | postmarketing | x | ||
| Palpitations | postmarketing | x | ||
| Pancreatitis | postmarketing | x | ||
| Pruritus | postmarketing | x | x | |
| Tachycardia | postmarketing | x | x | |
| Toothache | postmarketing | x | ||
| Urinary tract disorder | postmarketing | x | ||
| Urticaria | postmarketing | x | x | |
| Injection site reaction | postmarketing | x | x | |
| Malnutrition | postmarketing | x | ||
| Malaise | postmarketing | x | ||
| Decreased appetite | postmarketing | x | ||
| Abdominal discomfort | postmarketing | x | ||
| Abdominal pain upper | postmarketing | x | ||
| Pancreatitis necrotising | postmarketing | x | x | |
| Serum creatinine increased | postmarketing | x | ||
| Infestation NOS | postmarketing | x | ||
| Renal impairment | postmarketing | x | ||
| Abdominal pain | x | |||
| Neoplasm malignant | x | |||
| Carcinoma | x | |||
| Erythema | x | |||
| Upper respiratory tract infection | x | |||
| Papillary thyroid cancer | x | |||
| Injection site dermatitis | x | |||
Indications
Information about indications was extracted from the indications and usage sections of the labels.
Color scheme:
standard – alternative
| 100% | ||
| 75% | ||
| 50% | ||
| 10% | ||
| frequent (1% to 100%) | ||
| infrequent (0.1% to 1%) | ||
| rare (<0.1%) | ||
| postmarketing | ||
| 0% | ||
| no frequency information | ||
| not found on label |
